Abbvie Pharmaceutical Trading (Shanghai) Co., Ltd.

艾伯维医药贸易(上海)有限公司

Contact Info

Business Scope

AbbVie (NYSE: ABBV) is a global, research-based biopharmaceutical company formed on Jan 2nd, 2013 following a separation from Abbott. AbbVie China uses its knowledge and expertise to develop therapies that cover the four therapeutic areas of Immunology, Virology, Nephrology, and Anesthesiology. AbbVie China has also collaborated with medical institutes and regulatory authorities to roll out several clinical studies in hepatitis C, Oncology, Immunology, Neuroscience/Pain and Women’s Health.

艾伯维(纽约证交所:ABBV)是一家于2013年1月2日正式成立的全球研究型生物制药公司,从雅培公司拆分而来。艾伯维中国的产品线涉及多个疾病领域,涵盖免疫学领域、抗病毒学领域、肾脏学领域以及麻醉学领域。同时,艾伯维与中国的医学界和政府部门紧密合作,共同开展覆盖丙肝、肿瘤、免疫学、神经科学、疼痛和妇科健康等领域的临床研究